ArticleArthritis research & therapy2022
Clinical and pathological predictors of relapse in IgG4-related disease.
Article in Arthritis research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Risk factors for relapse of IgG4-related disease: a systematic review and meta‑analysis.Clinical rheumatology · 2025Pooled it
- IgG4-related disorders of the gastrointestinal tract: Experience from a tertiary care centre with systematic review of Indian literature.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024Pooled it
- IgG4-related disease in gastroenterology: from pathogenesis to clinical management and long-term outcomes.Journal of gastroenterology · 2026Review
- Extrafollicular Tph2-like cell dominant tissue pathotype is associated with relapse in IgG4-related disease.Rheumatology (Oxford, England) · 2026Article
- Article
- Reassessing the role of watchful waiting strategy for IgG4-related disease: a real-world study.Arthritis research & therapy · 2026Article
- IgG subclasses and their significance in pemphigus disease progression monitoring.Frontiers in immunology · 2026Article
- Beyond the Th2 paradigm: CD4+ cytotoxic T lymphocytes as key drivers of tissue damage and fibrosis in IgG4-related disease.Frontiers in immunology · 2026Review
- Does adjunctive endoscopic biliary drainage improve outcomes beyond glucocorticoids alone in IgG4-related pancreatobiliary disease?BMC gastroenterology · 2025Article
- Clinicopathological Pearls and Diagnostic Pitfalls in IgG4-Related Disease: Challenging Case Series and Literature Review.Diagnostics (Basel, Switzerland) · 2025Article
- IgG4-related disease presenting as central skull base osteomyelitis with deep neck abscesses: A case report.Medicine · 2025Article
- The Management of IgG4-Related Disease in Children: A Systematic Review.Children (Basel, Switzerland) · 2025Review
- IgG4-related disease - focus on digestive system involvement.Frontiers in immunology · 2025Review
- Successful rituximab treatment in IgG4-related coronary periarteritis: a case-based review.Rheumatology international · 2024Review
- Systematic analysis for clinical characteristics and outcomes of IgG4-related disease patients during the COVID-19 pandemic.Clinical rheumatology · 2024Article
- A case of IgG4-related disease manifesting as a spinal epidural mass.BJR case reports · 2024Article
- [Immunoglobulin G4 disease with pancreatic affectation: the mimicker of malignancy].Revista medica del Instituto Mexicano del Seguro Social · 2024Article
- IgG4-Related Membranous Nephropathy with Acute Nephrotic Syndrome During Successful Steroid Maintenance Treatment for Type 1 Autoimmune Pancreatitis.The American journal of case reports · 2023Article
- Investigating the Link Between Abdominal Pain, Weight Loss, and IgG4-Related Pancreatitis: A Case Report.Cureus · 2023Article
- IgG4-Related Disease Mimicking Unilateral Urothelial Carcinoma: A Rare Case Report and Literature Review.Clinical medicine insights. Case reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesIn IgG4-related disease, the relationship between pathological findings and relapse has not been well established. This study aimed to identify the clinical and pathological predictors of disease relapse in IgG4-RD.
methodsPatients with newly diagnosed IgG4-RD (n = 71) were enrolled between January 2011 and April 2020; all cases were pathologically confirmed. The clinical and pathological features were recorded in a database at baseline and each follow-up visit. Patients were followed up at least once a month via outpatient clinic examinations and telephone calls. Univariate and multivariate Cox regression analyses and receiver operating curve (ROC) analysis were used to identify the predictors of disease relapse and to assess their predictive value.
resultsOver a median follow-up of 26 (range, 6-123) months, 3/71 (4.2%) patients died. Of the remaining 68 patients, 47 (69.1%) patients had achieved clinical remission and 21 (30.9%) had suffered relapse at the last follow-up. The independent predictors of relapse were IgG4 ≥ 6.5 g/L (HR = 2.84, 95% CI: 1.11-7.23), IgG ≥ 20.8 g/L (HR = 4.11, 95% CI: 1.53-11.06), IgG4-RD responder index (RI) ≥ 9 (HR = 3.82, 95% CI: 1.28-11.37), and severe IgG4
conclusionsIn patients with IgG4-RD, IgG4 ≥ 6.5 g/L, IgG ≥ 20.8 g/L, IgG4-RD responder index (RI) ≥ 9, and severe IgG4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.